Unverricht-Lundborg disease (ULD) is a typical form of progressive myoclonus epilepsy (PME) associated with generalized tonic-clonic seizures (GTCS), action myoclonus, and only mild, nonprogressive cognitive defects. 1 The long-term evolution of ULD is characterized by the abatement of GTCS but persistence of myoclonus. 2 Prevalence is increased in Scandinavia and around the Mediterranean. ULD is a recessive disease with a point mutation and/or dodecamer expansion in the cystatin B gene on chromosome 21q. 3 In addition to this typical and fairly homogenous disease, a de novo mutation of KCNC1 has also been recently described in cystatin B-negative patients, 4 and the ULD concept has been enlarged to include patients with "action myoclonus renal failure" syndrome due to mutations in two other genes: PRICKLE1 and SCARB2. 5 In ULD, treatment options are limited, without etiologically oriented therapies. Recommended pharmacologic options include valproate (VPA), piracetam (PIR) usually at high doses, levetiracetam (LEV), topiramate, zonisamide, and clonazepam (CNZ), 5 whereas the effect of brivaracetam has been inconclusive. 6 Other antiepileptic drugs (AEDs) may have aggravating effects, for example, phenytoin 7 or lamotrigine. 8 Perampanel (PER) is a novel AED that selectively inhibits postsynaptic AMPA receptors, and its efficacy has been demonstrated in drug-resistant focal epilepsies, and more recently in primary GTCS. 9 Schorlemmer et al. 10 showed that PER may have a remarkable effect on seizures and myoclonus in Lafora's disease, a PME with a very severe phenotype. Thus we decided to use add-on PER in patients with ULD whose seizures were not satisfactorily controlled with recommended AEDs.
Patients and Methods
Among 32 patients with ULD regularly followed in two clinics (10 in Montpellier and 22 in Marseille), 12 patients had a disabling disease related to frequent seizures in 6 (GTCS and/or generalized clonic/myoclonic seizures without clear loss of consciousness [MS] ), and to invalidating action myoclonus in all. We initiated add-on PER between September 2014 and November 2015 (Table 1) . PER was introduced by 2 mg steps at 2-4 week intervals up to 6 mg, with possible dose reduction in case of side effects or dose increase in case of less than optimal efficacy. Patients and carers received comprehensive information on PER. No ethics committee was involved.
Patients were followed at 3-month intervals and encouraged to notify providers of any problems by phone between visits. They kept seizure logs that also reported the severity of myoclonus. At each visit, a complete clinical examination, with evaluation of resting and action myoclonus, gait, writing ability and feeding ability, as well as screening of side effects, occupational status, and overall well-being was recorded. The effect of PER was assessed at the latest follow-up or at discontinuation of the drug.
Results
Eleven patients (6 F, 5 M, aged 13-62 years) had classical ULD with EPM1 mutations, and a 43-year-old man had a severe phenotype (still without cognitive impairment after 35 years) and a de novo KCNC1 mutation ( Table 1 ). All were receiving polytherapy. They received PER during 3-21 months (median 16 months). All had a severe form of ULD; only five were able to walk without help (including three who lived independently but complained of invalidating myoclonus, two young women ages 13 and 16 who experienced severe fluctuations of myoclonus and numerous day-and nighttime MS and GTCS, and one who used a wheelchair for safety but was able to walk around her apartment).
Efficacy
Ten patients had a clear clinical response on myoclonus and five patients were able to reduce concomitant therapy including CNZ in all (patients 1, 3, 4, 5, and 6; Table 2 ). Patient 4 also decreased PIR (27-18 g/day) and patient 6 • Weight gain between 4 and 8 kg was reported by six patients (50%)
• Six patients reported (50%) psychological or behavioral changes, which occurred at an average dose of 5 mg/day also stopped LEV. Improvement of myoclonus was noted, sometimes as soon as with 2 mg. Among seven wheelchairbound patients, three regained the ability to walk (patients 1, 2, and 7) and two the ability to transfer between seats and stand up (patients 3 and 4). All patients with a positive effect on myoclonus also reported clearer speech, easier swallowing, and better use of their hands.
Epileptic seizures stopped on PER in the six patients who still had experienced GTCS and/or MS: patients 1, 2, 11, and 12 were still young with active epilepsy, and patient 3 who had a severe form with a KCNC1 mutation. Patient 6 no longer had falls provoked by sudden, serial myoclonic jerks in his legs (considered as MS). In patient 11, the numerous myoclonic and myoclonic tonic-clonic seizures that she experienced each night disappeared, although she still had some nocturnal awakenings, albeit without any myoclonus (Fig. 1) . Patient 2 had to stop PER because of severe behavioral side-effects, and the seizures recurred.
We noted an abatement of efficacy in two patients; however, both retained a marked beneficial effect: patient 3 lost some of the benefit on myoclonus after 3 months and PER was reduced to 3 mg/day, but remained seizure free and was still able to stand up and walk with support; patient 4 experienced slight increase of myoclonus at 4 months, and had to decrease dosage due to side-effects; she still retains some beneficial effect.
Two patients (8 and 10) asked to stop PER after 3 months at 4 and 6 mg/day, without significant improvement of myoclonus (both had been already seizure free for >10 years). Patient 8 asked to stop the medication after 3 months because she felt increased anxiety, and patient 10 because of the overall treatment load. One year later, the latter developed a renal stone and had to stop zonisamide, which caused her to resume PER with follow-up of 3 months without side-effects or efficacy at 4 mg.
Side effects
Weight gain between 4 and 8 kg was reported by six patients (50%), including two young teenagers (patients 11 and 12) who were underweight before PER; four adult patients complained about weight gain, and reported both increased appetite and better feeding ability (patients 1-4); all these patients were concomitantly on VPA (Table 2) . Besides weight gain, six patients reported other sideeffects. In all cases, these exclusively involved psychological or behavioral changes (patients 1, 2, 4, 7, 8, and 9), which occurred at an average dose of 5 mg, and led to withdrawal of PER in three cases (including one without improvement [patient 8] and two despite major improvement [patients 2 and 9]), and resolved after dose reduction in three (patients 1, 4, and 7). The most disturbing incidents involved irritability (three cases) with violence in one case, anxiety/depression (three cases), and hallucinations (one case).
Patient 1 reported irritability at 6 mg/day, which resolved at 4 mg/day; she had experienced a major benefit, regaining the ability to walk, with total control of seizures. Patient 2, with marked improvement, had severe behavioral problems, with aggression at 6 mg/day of PER; he was already on neuroleptics because he did not tolerate the frustrations of daily life. Dose was reduced to 4 mg/day, without abatement of aggressivity, and PER was stopped after 9 months. It was reintroduced 3 months later at 2 mg/day, but aggressivity recurred and PER was stopped again despite a major effect on myoclonus and seizures. Patient 4 experienced irritability at 4 mg/day, and hallucinations at 6 mg/day, with significant improvement of myoclonus; PER was reduced to 2 mg/day with persisting positive effect (clearer speech, ability to eat and drink by herself). Patient 7 experienced anxiety and depression at 8 mg/day, all of which resolved at 6 mg/day. Patient 8 asked to stop at 4 mg/day after 3 months because she felt anxious and had not noted any improvement. Patient 9 asked to stop PER at 6 mg/day because of unbearable anxiety mixed with depression, despite a moderate improvement of myoclonus.
Discussion
Among PMEs, ULD stands out as a comparatively mild form, with little or no reduction in life expectancy. 2, 5 Treatment remains purely symptomatic. The anticonvulsant and antimyoclonic effects of AEDs may be superimposed on the natural history of the disease, which seems to stabilize around age 25-30. There is clearly a spectrum of severity, and at a late stage of ULD, some patients are able to lead fairly normal lives (working, raising a family, driving, and so on), whereas others are wheelchair-bound and severely restricted. Despite recent advances in the overall prognosis of ULD, due both to social help and to more specific and efficient AEDs, many patients are expecting better therapies, many patients are still expecting better therapies.
Very little is known about the effect of PER in myoclonic epilepsies, or more generally in generalized and encephalopathic epilepsies; the fact that PER has been active against primary GTCS is of course encouraging. 9 The reports of an antimyoclonic and antiseizure effect in Lafora disease (which we confirmed in recent personal observations in Lafora disease) has raised the possibility that PER may be useful in other types of PME. [10] [11] [12] The unwanted side-effect profile reported in patients who receive PER for focal seizures is characterized by a high incidence of fatigue, somnolence, and dizziness 13 ; we never noted these, but found a higher prevalence (50%) of psychological and behavioral side-effects, rarely noted in the large controlled studies in focal epilepsy. These psychiatric adverse side effects led to withdrawal of PER in three cases and dose reduction in three, with abatement of the problems. It is not clear whether the high incidence of such side effects is specifically related to ULD, but we think that this is unlikely, since there was no major incidence of these in previous studies with PIR or brivaracetam. 6, 14 Improvement of myoclonus was noted in >80%, leading to a reduction of the concomitant therapy in five patients. Three patients were able to walk again, and one autonomous patient ceased to fall suddenly. Those who still had seizures before PER (n = 5) no longer reported any while on PER, but patient 2 relapsed when he had to stop PER. Some abatement of efficacy was seen in two patients who still retained some benefit and decided to continue on PER, including the patient with the most marked benefit (patient 3), 3 months after initiation, and patient 4, after 4 months. However, five patients have remained on PER for at least 16 months without any decrease in efficacy. Such abatement had been described in patients who had experienced a spectacular effect of PIR. 14 In conclusion, PER has shown antimyoclonic and/or anticonvulsant efficacy in a small group of ULD patients and should thus be tried in patients who are not satisfactorily controlled by the usual, recommended drugs. In some patients, doses as low as 2 mg/day may bring significant relief, and should therefore be tried first without systematic uptitration. Its use is limited by the occurrence of frequent psychological and behavioral side-effects: patients should thus be closely warned and monitored, with higher doses of around 6 mg/day or above being likely risk factors.
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